Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823]

Citations

WEB OF SCIENCE

0
Citations

SCOPUS

1

초록

In the original publication of this paper, the second graph in Figure 4B was erroneously identical with fourth graph in Figure 4B and correct version is provided below. We apologize for any inconvenience that may have been caused. The original article has been corrected as of 27th February 2025. © 2025 by Korean Association for the Study of the Liver.

제목
Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823]
저자
Yim, Sun Young; Lee, Sung Hwan; Baek, Seung-Woo; Sohn, Bohwa; Jeong, Yun Seong; Kang, Sang-Hee; Park, Kena; Park, Hyewon; Lee, Sunyoung S; Kaseb, Ahmed O; Park, Young Nyun; Leem, Sun-Hee; Curran, Michael A; Kim, Ji Hoon; Lee, Ju-Seog
DOI
10.3350/cmh.2024.0333e
발행일
2025-04
유형
Correction
저널명
Clinical and Molecular Hepatology
권
31
호
2
페이지
669 ~ 670